Effects of antiplatelet agents in combination with endothelial cell seeding on small-diameter Dacron vascular graft performance in the canine carotid artery model.
The purpose of this study was to assess the success of endothelial cell-seeded and non-seeded small-diameter vascular grafts in dogs medicated with antiplatelet agents. Eighty dogs underwent bilateral carotid artery replacements with 6 cm lengths of 4 mm I.D. double-velour Dacron grafts. In each dog one graft was seeded with enzymatically derived autologous endothelial cells; the contralateral graft was nonseeded. The following anti-platelet medications were administered beginning 4 days preoperatively: aspirin (5 grains every day); dipyridamole (50 mg twice a day); aspirin plus dipyridamole (5 grains each day plus 50 mg twice a day); aspirin (1.25 grains every other day); ibuprofen (10 mg/kg/day); U-53,059, a cyclooxygenase inhibitor (3 mg/kg/day); and U-63557A, a thromboxane synthase inhibitor (10 mg/kg/day). Grafts were harvested 5 weeks postoperatively. Graft success was evaluated by patency, thrombus-free surface area, area endothelialized, and graft production of prostacyclin. None of the medications prevented neoendothelialization of seeded grafts. Mean patencies of endothelial cell-seeded grafts from medicated dogs were significantly greater than mean patencies of endothelial cell-seeded grafts from nonmedicated dogs. The cyclooxygenase inhibitors best maintained patency in nonseeded grafts. Thrombus-free surface areas of endothelial cell-seeded grafts from medicated dogs were significantly greater than from nonseeded control grafts from the medicated dogs. All medications impaired prostacyclin synthesis. We conclude that the combination of endothelial cell seeding plus antiplatelet medication is most efficacious in small-vessel grafting success and that high levels of prostacyclin production by vascular grafts are not necessary to maintain patency in dogs medicated with antiplatelet agents.
Schmidt
S P
SP
Hunter
T J
TJ
Falkow
L J
LJ
Evancho
M M
MM
Sharp
W V
WV
D000818:Animals; D001241:Aspirin / Q000627:therapeutic use; D001572:Benzofurans / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects*; D001807:Blood Vessel Prosthesis; D002339:Carotid Arteries / Q000601:surgery; D004176:Dipyridamole / Q000627:therapeutic use; D004285:Dogs; D004727:Endothelium / Q000166:cytology*; D005260:Female; D006083:Graft Occlusion, Vascular / Q000517:prevention & control; D007052:Ibuprofen / Q000627:therapeutic use; D008297:Male; D011093:Polyethylene Terephthalates; D011897:Random Allocation; D013927:Thrombosis / Q000517:prevention & control; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors
D001572:Benzofurans; D011093:Polyethylene Terephthalates; D004176:Dipyridamole; D013930:Thromboxane-A Synthase; C039936:furegrelate; D001241:Aspirin; D007052:Ibuprofen